Introduction
============

Breast cancer is one of the most common female cancers, accounting for approximately 28% of all female cancers and the second leading cause of cancer-related deaths in women.[@b1-ott-9-431] Progress has been made to the earlier diagnosis and better treatment of breast cancer during the past few decades, leading to the 5-year survival rates of breast cancer patients at approximately 85%. However, distant metastasis and recurrence still occur and result in poor prognosis. Therefore, there is an urgent need for identifying novel biomarkers that can be used to screen high-risk patients and help predict the progression and prognosis of breast cancer.[@b2-ott-9-431]--[@b4-ott-9-431]

Cluster of differentiation 44 (CD44) is a complex transmembrane glycoprotein that is encoded by the *CD44* gene on chromosome 11p13.[@b5-ott-9-431] CD44 consists of seven extracellular domains, a transmembrane domain, and a cytoplasmic domain.[@b6-ott-9-431] CD44 has several isoforms, including CD44s and CD44v.[@b7-ott-9-431],[@b8-ott-9-431] Functionally, CD44 was initially identified as the receptor for the extracellular matrix component, hyaluronic acid (HA), and was involved in multiple physiological and pathological processes, such as angiogenesis, cell adhesion, inflammation, and cancer development.[@b9-ott-9-431] In addition, CD44 has been reported to play important roles in cell proliferation, motility, and survival.[@b9-ott-9-431],[@b10-ott-9-431] A recent study indicated that CD44 expression was elevated in tumor-initiating cells in many kinds of cancer.[@b11-ott-9-431] Thus, CD44 is thought to be a biomarker for cancer stem cells (CSCs).[@b12-ott-9-431] Subsequent functional studies have shown that CD44 is involved in tumorigenesis and metastasis in many cancer types such as colon,[@b13-ott-9-431]--[@b15-ott-9-431] bladder,[@b16-ott-9-431] gastric,[@b17-ott-9-431] and breast cancers.[@b18-ott-9-431]--[@b20-ott-9-431] Studies on CD44 expression have suggested a correlation between it and clinical outcome in patients with breast cancer. It has been shown that the overexpression of CD44 has a bad impact on survival of breast cancer patients,[@b21-ott-9-431] but different results were also reported.[@b22-ott-9-431] Currently, the role of CD44 in breast cancer has not been clearly defined. To investigate the role of CD44 in breast cancer, a meta-analysis was performed. Our analysis indicated that CD44 expression was elevated in basal-type breast cancer. Currently, there are no effectively targeted therapies for patients with this subtype of breast cancer and prognosis is poor compared with other subtypes.[@b23-ott-9-431] Since *CD44* expression is associated with mesenchymal and CSC signature and predicts poor prognosis,[@b24-ott-9-431],[@b25-ott-9-431] our study indicates that CD44 may represent a potential therapeutic target for basal-type breast cancer.

Materials and methods
=====================

Database and literature search
------------------------------

We performed a comprehensive search of relevant Gene Expression Omnibus (GEO) databases for *CD44* mRNA expression and literatures for CD44 protein level. First, we searched the ArrayExpress for uploaded databases within the topic of interest, using the search terms "breast cancer" by filtering Homo sapiens, RNA array, array assay, and all arrays. We also searched Oncomine for databases of breast cancer with mRNA information of *CD44*. Second, PubMed was reviewed to identify potentially relevant literatures using the search terms associated with CD44 ("CD44 antigen", "hyaluronan-binding protein", "receptors", "hyaluronan") and breast cancer ("breast neoplasm", "breast tumor", "breast carcinoma", "mammary cancer"). The references were also searched to discover additional relevant publications.

Inclusion and exclusion criteria
--------------------------------

This meta-analysis collected data aimed at evaluating the role of CD44 expression in breast cancer at both mRNA and protein levels. Databases that met the following criteria were included: 1) the datasets were about breast cancer; 2) *CD44* expression was measured in these databases; 3) the sample capacity was \>50; and 4) clinical information of patients was showed in these databases. The exclusion criteria were as follows: 1) the datasets were about animals such as mice and rabbits and 2) the datasets were about DNA, rather than RNA. When several databases shared the same patient population, only the latest and most complete datasets were included. Literature that met the following criteria were included: 1) patients recruited in the study were pathologically diagnosed with breast cancer; 2) CD44 expression was measured in breast cancer tissues; and 3) the hazard ratio (HR)/odds ratio (OR) and corresponding 95% confidence interval (CI) were reported or could be statistically extracted from the study. The exclusion criteria were as follows: 1) reviews, case reports, comments, letters, and conference abstract and 2) ineligible samples or those where the required data were not available. When several articles were from the same patient population, the latest or most complete article was included.

Data extraction
---------------

Data were abstracted in a standardized collection form, with information recorded as follows: last name of first author, publication year, country, duration, tumor--node--metastasis (TNM) stage, quality score, detection, and cutoff values for CD44. We reviewed ArrayExpress and Oncomine and identified 23 independent human breast cancer microarray datasets with *CD44* mRNA expression and clinical data. Overall survival (OS), recurrence-free survival (RFS), and metastasis-free survival (MFS) were evaluated by Cox proportional HRs and 95% CIs using these numerical data. If HRs were not given in an article, we used the methods described by Tierney et al to calculate the statistical variables from published survival curves.[@b26-ott-9-431] The quality of observational studies was evaluated according to the Newcastle--Ottawa Quality Assessment Scale. This scale reflects patient selection, study comparability, and outcomes and is based on the identification of eight sources of potential study bias. Two reviewers performed the literature search, study selection, and data abstraction independently, and disagreements between the reviewers were solved by discussion.

Statistical analysis
--------------------

Statistical analysis was performed based on the requirements of the meta-analysis of observational studies. The STATA software package (Version 12.0; StataCorp LP, College Station, TX, USA) was utilized to perform the meta-analysis. The random-effect model was employed when heterogeneity was present, and the fixed-effect model was used when homogeneity was demonstrated. The heterogeneity of publication was evaluated by means of the chi-square-based *Q* statistic and inconsistency index (*I*^2^) statistic. Begg's and Egger's tests were employed to assess the publication bias. HRs were employed to assess the survival outcome of patients with breast cancer who had high CD44 expression, and HR \>1 indicated that high expression of CD44 predicted worse survival of patients. The OR and 95% CI were used to evaluate the association between CD44 expression and clinicopathological parameters.

Results
=======

Search results
--------------

The flow diagram for the identification of relevant studies is shown in [Figure 1](#f1-ott-9-431){ref-type="fig"}. A total of 1,472 datasets and 1,147 literatures were initially identified by our search approach. For GEO databases, after the sample capacity and clinical information were checked, 23 datasets[@b21-ott-9-431],[@b27-ott-9-431]--[@b48-ott-9-431] met the criteria for this analysis. For 1,147 literatures, after title/abstract scanning and full-text reading, 12 eligible articles[@b22-ott-9-431],[@b49-ott-9-431]--[@b59-ott-9-431] were included. [Table 1](#t1-ott-9-431){ref-type="table"} shows the features of these 23 studies. Four Gene Expression Omnibus series (GSE) datasets were analyzed for finding the difference in *CD44* mRNA expression between breast tumors and normal breast tissues. For finding the association between *CD44* mRNA expression and TNM stage, tumor grade, estrogen receptor (ER) status, progesterone receptor (PR) status, human epidermal growth factor receptor-2 (HER2) status, and basal-like breast cancer, four, 13, eleven, four, six, and seven GSE datasets, respectively, were analyzed. To estimate the prognostic role of *CD44* mRNA expression in OS, RFS, and MFS, eleven, ten, and nine, respectively, GSE datasets were adopted. Three GSE datasets were analyzed for the association between *CD44* mRNA expression and the RFS in basal-like breast cancer. [Table 2](#t2-ott-9-431){ref-type="table"} shows the characteristics of 12 studies. A total of nine, eight, seven, and five articles were assessed for the correlation between CD44 protein abundance and ER status, PR status, HER2 status, and basal-like breast cancer, respectively. Clinical stages I and II were grouped as early-stage disease, whereas stages III and IV were grouped as late-stage disease. Clinical T stages 1 and 2 were identified as early T stage, and 3 and 4 were identified as late T stage. Clinical N stages 1 and 2 were classified into early N stage, and 3 and 4 were classified into late N stage. Histological grades I and II were pooled as low-grade disease, and III and IV were pooled as high-grade disease.

CD44 expression correlates with clinicopathological features of breast cancer
-----------------------------------------------------------------------------

Eighteen studies assessed the association between *CD44* mRNA expression and tumor clinicopathological features. Our meta-analysis indicated that *CD44* expression in breast cancer tissues was increased when compared with that in normal breast tissues (pooled OR =1.15, 95% CI: 1.02--1.31, Cochran's *Q* test *P*=0.070, and *I*^2^=57.5%; [Figure 2A](#f2-ott-9-431){ref-type="fig"}). However, there was no statistically significant correlation between *CD44* expression and tumor TNM stage (pooled OR =1.10, 95% CI: 0.94--1.29, Cochran's *Q* test *P*=0.039, and *I*^2^=64.1%; [Figure 2B](#f2-ott-9-431){ref-type="fig"}), T stage (pooled OR =1.00, 95% CI: 0.84--1.19, Cochran's *Q* test *P*=0.137, and *I*^2^=33.9%; [Figure 2C](#f2-ott-9-431){ref-type="fig"}), and N status (pooled OR =0.98, 95% CI: 0.91--1.06, Cochran's *Q* test *P*=0.006, and *I*^2^=57.8%; [Figure 2D](#f2-ott-9-431){ref-type="fig"}). Patients with breast cancer with higher histological grade were likely to have a higher content of CD44 at both mRNA (pooled OR =1.15, 95% CI: 1.06--1.25, Cochran's *Q* test *P*=0.582, and *I*2=0.0%; [Figure 2E](#f2-ott-9-431){ref-type="fig"}) and protein levels (pooled OR =1.11, 95% CI: 1.02--1.20, Cochran's *Q* test *P*=0.055, and *I*^2^=45.8%; [Figure 2F](#f2-ott-9-431){ref-type="fig"}).

CD44 expression correlates with molecular subtypes of breast cancer
-------------------------------------------------------------------

The association of CD44 expression with ER, PR, HER2 status, and basal-like breast cancer was also analyzed. At the mRNA level, *CD44* was inversely correlated with ER status (pooled OR =1.93, 95% CI: 1.69--2.20, Cochran's *Q* test *P*=0.002, and *I*^2^=63.9%; [Figure 3A](#f3-ott-9-431){ref-type="fig"}), PR status (pooled OR =1.31, 95% CI: 1.14--1.51, Cochran's *Q* test *P*=0.173, and *I*^2^=39.8%; [Figure 3B](#f3-ott-9-431){ref-type="fig"}), and HER2 status (pooled OR =1.05, 95% CI: 1.00--1.10, Cochran's *Q* test *P*=0.000, and *I*^2^=82.4%; [Figure 3C](#f3-ott-9-431){ref-type="fig"}). Interestingly, *CD44* mRNA expression was higher in basal-like tumors than in the luminal subtype of breast cancer (pooled OR =2.08, 95% CI: 1.72--2.52, Cochran's *Q* test *P*=0.001, and *I*^2^=72.1%; [Figure 3D](#f3-ott-9-431){ref-type="fig"}). At the protein level, CD44 expression was conversely linked to ER status (pooled OR =1.31, 95% CI: 1.15--1.48, Cochran's *Q* test *P*=0.329, and *I[@b2-ott-9-431]*=12.7%; [Figure 3E](#f3-ott-9-431){ref-type="fig"}). However, there is no statistical significance in terms of an association between CD44 expression and PR status (pooled OR =0.99, 95% CI: 0.90--1.08, Cochran's *Q* test *P*=0.816, and *I*^2^=0.0%; [Figure 3F](#f3-ott-9-431){ref-type="fig"}) or HER2 status (pooled OR =1.03, 95% CI: 0.98--1.08, Cochran's *Q* test *P*=0.008, and *I[@b2-ott-9-431]*=65.5%; [Figure 3G](#f3-ott-9-431){ref-type="fig"}) at protein level. Moreover, CD44 protein abundance in basal-like tumors was much higher than in the luminal subtype of breast cancer (pooled OR =2.11, 95% CI: 1.67--2.68, Cochran's *Q* test *P*=0.017, and *I*^2^=66.9%; [Figure 3H](#f3-ott-9-431){ref-type="fig"}).

CD44 mRNAexpression correlates with breast cancer survival
----------------------------------------------------------

The association between *CD44* expression level and breast cancer patient survival was analyzed. Our analysis indicated that there was a significant correlation between *CD44* overexpression and the poor OS rate (pooled OR =1.27, 95% CI: 1.04--1.55, Cochran's *Q* test *P*=0.505, and *I*^2^=0.0%; [Figure 4A](#f4-ott-9-431){ref-type="fig"}). However, *CD44* expression was not statistically significant in terms of an association between the RFS rate (pooled OR =1.04, 95% CI: 0.89--1.23, Cochran's *Q* test *P*=0.417, and *I*^2^=2.4%; [Figure 4B](#f4-ott-9-431){ref-type="fig"}) and the MFS rate (pooled OR =1.30, 95% CI: 0.89--1.90, Cochran's *Q* test *P*=0.010, and *I*^2^=60.2%; [Figure 4C](#f4-ott-9-431){ref-type="fig"}). Subcategory analyses according to the molecular classification of breast cancer were also performed. We found that higher *CD44* mRNA expression correlated with worse RFS in patients with basal-like breast cancer (pooled OR =1.84, 95% CI: 1.17--2.87, Cochran's *Q* test *P*=0.574, and *I*^2^=0.0%; [Figure 4D](#f4-ott-9-431){ref-type="fig"}). However, there was no statistically significant correlation between *CD44* mRNA expression and the survival performance of patients with luminal subtype of breast cancer. The latter included the OS rate (pooled OR =1.14, 95% CI: 0.73--1.79, Cochran's *Q* test *P*=0.296, and *I*^2^=17.8%), the RFS rate (pooled OR =0.99, 95% CI: 0.75--1.31, Cochran's *Q* test *P*=0.258, and *I*^2^=23.5%), and the MFS rate (pooled OR =1.25, 95% CI: 0.65--2.38, Cochran's *Q* test *P*=0.010, and *I*^2^=69.7%). Kaplan--Meier survival analysis of GSE3143 demonstrated that there was a significant effect of *CD44* on OS (*P*=0.016; [Figure 5A](#f5-ott-9-431){ref-type="fig"}). Kaplan--Meier survival analysis of GSE6532 showed that there were no significant effects of *CD44* on the RFS in all population of breast cancer (*P*=0.743; [Figure 5B](#f5-ott-9-431){ref-type="fig"}), but it was inversely associated with the MFS rate (*P*=0.007; [Figure 5C](#f5-ott-9-431){ref-type="fig"}). Kaplan--Meier survival analysis of GSE25066 demonstrated that there was a significant effect of *CD44* on the RFS in basal-like breast cancer (*P*=0.023; [Figure 5F](#f5-ott-9-431){ref-type="fig"}) but no significant association between *CD44* mRNA expression and the RFS in all molecular subtypes (*P*=0.136; [Figure 5D](#f5-ott-9-431){ref-type="fig"}) or in luminal breast cancer (*P*=0.215; [Figure 5E](#f5-ott-9-431){ref-type="fig"}). In all, the results from the *CD44* mRNA profile indicated that higher *CD44* expression predicted a poorer prognosis in patients with breast cancer subtype.

CD44 correlates with epithelial--mesenchymal transition and CSC markers
-----------------------------------------------------------------------

The association between *CD44* and epithelial*--*mesenchymal transition (EMT) or CSC-related genes was also assessed. The results indicated that there was a positive relation between *CD44* and *SNAI1* (*R*=0.87, *P*\<0.001; [Figure 6A](#f6-ott-9-431){ref-type="fig"}), *SLUG* (*R*=0.66, *P*\<0.001; [Figure 6B](#f6-ott-9-431){ref-type="fig"}), *ZEB1* (*R*=0.82, *P*\<0.001; [Figure 6C](#f6-ott-9-431){ref-type="fig"}), *CDH2* (*R*=0.83, *P*\<0.001; [Figure 6D](#f6-ott-9-431){ref-type="fig"}), *TWIST* (*R*=0.40, *P*\<0.001; [Figure 6E](#f6-ott-9-431){ref-type="fig"}), and *VIM* (*R*=0.72, *P*\<0.001; [Figure 6F](#f6-ott-9-431){ref-type="fig"}). The association between *CD44* and CSC markers was also evaluated. It was shown that *CD44* was positively associated with *ALDH1* (*R*=0.53, *P*\<0.001; [Figure 6G](#f6-ott-9-431){ref-type="fig"}), *SOX2* (*R*=0.86, *P*\<0.001; [Figure 6H](#f6-ott-9-431){ref-type="fig"}), *NANOG* (*R*=0.78, *P*\<0.001; [Figure 6I](#f6-ott-9-431){ref-type="fig"}), *KLF4* (*R*=0.74, *P*\<0.001; [Figure 6J](#f6-ott-9-431){ref-type="fig"}), *MYC* (*R*=0.68, *P*\<0.001; [Figure 6K](#f6-ott-9-431){ref-type="fig"}), and *OCT4* (*R*=0.87, *P*\<0.001; [Figure 6L](#f6-ott-9-431){ref-type="fig"}).

Publication bias
----------------

Publication bias statistics were obtained using Begg's and Egger's tests, and did not indicate any significant publication bias; *CD44* mRNA expression: breast cancer: Begg's test *P*=0.734, Egger's test *P*=0.905; TNM stage: Begg's test *P*=1, Egger's test *P*=0.796; tumor size: Begg's test *P*=0.466, Egger's test *P*=0.362; lymph node metastasis: Begg's test *P*=0.945, Egger's test *P*=0.097; histological grade: Begg's test *P*=0.246, Egger's test *P*=0.948; expression of ER: Begg's test *P*=0.640, Egger's test *P*=0.313; expression of PR: Begg's test *P*=1, Egger's test *P*=0.809; expression of Her2: Begg's test *P*=0.260, Egger's test *P*=0.494; basal-like breast cancer: Begg's test *P*=1, Egger's test *P*=0.77; OS: Begg's test *P*=0.436, Egger's test *P*=0.436; RFS: Begg's test *P*=0.592, Egger's test *P*=0.612; MFS: Begg's test *P*=0.251, Egger's test *P*=0.146; OS of luminal breast cancer: Begg's test *P*=1, Egger's test *P*=0.642; RFS of luminal breast cancer: Begg's test *P*=0.260, Egger's test *P*=0.436; MFS of luminal breast cancer: Begg's test *P*=0.806, Egger's test *P*=0.528; RFS of basal-like breast cancer: Begg's test *P*=1, Egger's test *P*=0.698. Protein level: histological grade: Begg's test *P*=0.917, Egger's test *P*=0.911; expression of ER: Begg's test *P*=0.917, Egger's test *P*=0.009; expression of PR: Begg's test *P*=0.266, Egger's test *P*=0.743; expression of HER2: Begg's test *P*=1, Egger's test *P*=0.434; and basal-like breast cancer: Begg's test *P*=0.462, Egger's test *P*=0.065.

Discussion
==========

Molecular characterization contributes to the discovery of biomarkers and potential targets for anticancer therapy, which is the basis of precise medicine.[@b60-ott-9-431] Accumulating evidence suggests that CD44 is a marker of tumor-initiating cells, plays a role in tumorigenesis, and linked to the progression of breast cancer.[@b15-ott-9-431],[@b61-ott-9-431]--[@b63-ott-9-431] CD44 was also reported to have an impact on the prognosis of breast cancer including recurrence[@b64-ott-9-431] and chemoresistance.[@b65-ott-9-431] Uchino et al found that the upregulation of CD44 represented an aggressive subtype in noninvasive breast cancer cell.[@b19-ott-9-431] The blockade of CD44 intracellular domain (CD44ICD) cleavage and nuclear translocation have been shown in cancer cells. The activation of CD44 by HA promoted the chemoresistance in breast cancer cells.[@b66-ott-9-431] CD44/cellular prion protein interaction has an effect on the responses to neoadjuvant chemotherapy in patients with breast cancer and exhibits aggressive behaviors of breast cancer cells.[@b67-ott-9-431] CD44--STAT3 interaction plays an important role in breast cancer invasion.[@b64-ott-9-431] Moreover, Cox regression analysis showed that ezrin and CD44 co-expression were independent prognostic factors of breast cancer.[@b68-ott-9-431]

In our meta-analysis, the role of CD44 in breast cancer, at both mRNA and protein levels, was investigated. We found that the mRNA level of *CD44* was higher in breast tumor tissues than in normal breast tissues, indicating that *CD44* might participate in the tumorigenesis of specific subtypes of breast cancer. Moreover, our meta-analysis suggests a positive association between histological grade and the CD44 levels. This would indicate that patients with high expression of *CD44* mRNA might have poor prognosis, because high-grade tumor tends to be more aggressive and tends toward early recurrence. It has been shown that CD44 was activated in breast cancer cells but inactivated in normal cells in vitro and in vivo.[@b69-ott-9-431] However, the association between *CD44* mRNA expression and TNM stage, T stage, and N stage was not statistically significant.

Based on the status of ER, PR, and HER2, breast cancer could be divided into five molecular subtypes, including normal-like, luminal A, luminal B, HER2-overexpressing, and basal-like breast cancer.[@b70-ott-9-431],[@b71-ott-9-431] Each subtype exhibits distinctive expression patterns of specific molecules, clinical outcomes, and responses to adjuvant chemotherapy.[@b33-ott-9-431],[@b72-ott-9-431],[@b73-ott-9-431] Some studies indicated that CD44 expression was negatively associated with the status of ER,[@b49-ott-9-431],[@b53-ott-9-431],[@b74-ott-9-431],[@b75-ott-9-431] PR,[@b74-ott-9-431] and HER2.[@b53-ott-9-431],[@b74-ott-9-431] At the mRNA level, our meta-analysis showed that *CD44* expression was significantly inversely associated with the status of ER, PR, and HER2. Consistently, significant correlation between CD44 expression and ER status was found at its protein level. Among the five molecular subtypes, basal-like breast cancer tends to be more aggressive and there is a lack of effective therapy, resulting in poorer outcomes.[@b76-ott-9-431] Jang et al showed that CD44(+)/CD24(−) subpopulation was much higher in basal-like breast cancer than that in non-basal-like cancer,[@b24-ott-9-431] and that CD44(+)/CD24(−) cells had a high capacity of proliferation, migration, invasion, and tumorigenesis.[@b25-ott-9-431] By providing a highly hydrated environment favoring cellular invasion, HA--CD44 interaction contributed to the progression of basal-like breast cancer.[@b77-ott-9-431] Consistently, our results showed that CD44 expression was higher in basal-like breast cancers than in luminal breast cancer or all other subtypes.

CD44 is critical for regulating EMT.[@b19-ott-9-431] CD44 activation can lead to the expression of epithelial growth factor receptor and the activation of phosphoinositide-3 kinase/Akt. CD44 also upregulates N-cadherin, α-actin, vimentin, fibronectin, and other EMT markers. The latter is involved in cell invasion and migration.[@b78-ott-9-431] By knocking down CD44 expression in human hepatoma cell line HLE, the levels of snail and vimentin were decreased, which was correlated with a less-mesenchymal-like phenotype.[@b79-ott-9-431] Consistently, our analysis indicated that *CD44* expression was significantly associated with mesenchymal gene *SNAI1*, *SLUG*, *ZEB1*, *CDH2*, and *TWIST*.

CD44 is a well-known breast CSC marker that plays a role in promoting tumorigenesis of breast cancer through interaction with its intracellular domain and stemness factors such as NANOG, OCT4, and SOX2.[@b20-ott-9-431] Analysis of gene expression profiles revealed that *CD44* is closely associated with key stem cell genes *ALDH1*, *SOX2*, *NANOG*, *KLF4*, *OCT4*, and *MYC*. Since CSC is thought to be a major cause for cancer progression and therapeutic resistance,[@b80-ott-9-431],[@b81-ott-9-431] the role of *CD44* in breast cancer might be attributable to those stem cell factors.

Studies identified several genes that might have prognostic values for breast cancer, including urokinase plasminogen activator and its inhibitor[@b82-ott-9-431] and the genes in the *DACH--EYA--SIX* pathway.[@b83-ott-9-431]--[@b85-ott-9-431] Interestingly, insulin-like growth factor 1 receptor expression showed different prognostic values for patients with different subtypes of breast cancer.[@b86-ott-9-431] Ubiquitin protein D and KLF4 have been reported to predict the response to chemotherapy.[@b87-ott-9-431],[@b88-ott-9-431] Accumulating evidence indicates that CD44 could be a prognostic biomarker for breast cancer.[@b12-ott-9-431] Our meta-analysis suggested that *CD44* high expression could be a prognostic marker for OS. Although there was no association between *CD44* expression and RFS in the whole population of breast cancer, a significant association between *CD44* mRNA expression and RFS in patients with basal-like breast cancer was identified. This agrees with a previous study showing that patients with CSC markers CD44(+)/CD24(−) had a lower survival rate, while patients without this subpopulation had a higher survival rate in basal-like breast cancer.[@b89-ott-9-431] Some studies showed that CD44 expression was positively correlated with the metastasis of breast carcinoma,[@b75-ott-9-431] but others reported opposite results.[@b90-ott-9-431] Martin and Jiang found that CD44 was markedly reduced in patients with ductal breast cancer with metastasis.[@b91-ott-9-431] Our meta-analysis showed that *CD44* expression has no significant effect on the MFS ([Figure 4C](#f4-ott-9-431){ref-type="fig"}), but some GSE data did demonstrate that *CD44* was correlated with the MFS ([Figure 5C](#f5-ott-9-431){ref-type="fig"}). Breast cancer metastasis is a complicated process which is involved in the alteration of a number of proteins, including epithelial growth factor receptor and transforming growth factor-β.[@b92-ott-9-431] Considering the complex regulation of the metastasis process of breast cancer, the effects of *CD44* on the MFS might be covered by other factors.

Heterogeneity tests are essential to a meta-analysis. In this study, the evidence of minor heterogeneities was observed with respect to TNM stage, ER status, molecular subtypes, and the MFS. However, there was substantial heterogeneity with respect to HER2 status. This result might be due to the following aspects: 1) The sample size is limited, indicating that multicenter prospective studies are needed. 2) The variations in assessing *CD44* mRNA expression might also contribute to heterogeneity. The cutoff value was estimated in 23 studies using the median *CD44* level measured by gene microarray. 3) Publication bias is worth considering in meta-analyses. This study was a meta-analysis based on GEO datasets and published studies. Thus, our analysis has the following limitations: 1) we cannot exclude the publication bias; 2) the relevant papers were limited; and 3) methods and cutoff values used to assess CD44 expression were different.

Conclusion
==========

In conclusion, our meta-analysis suggests that CD44 might be a prognostic factor for patients with breast cancer, particularly for the basal-like breast cancer. Since CD44 expression was elevated in basal-type breast cancer and its expression levels were correlated with EMT and CSC signatures, these considerations might partially explain why patients with basal-type breast cancer have a high risk of metastasis and relapse. Moreover, our meta-analysis might help identify subpopulation of patients with breast cancer for CD44-based therapy in the future.
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![Flow diagram of article selection.\
**Notes:** (**A**) Initial dataset search and selection process for CD44 mRNA expression in this meta-analysis. (**B**) Initial dataset search and selection process for CD44 protein abundance in this meta-analysis.\
**Abbreviation:** CD44, cluster of differentiation 44.](ott-9-431Fig1){#f1-ott-9-431}

![Correlation between *CD44* mRNA expression or CD44 protein and breast cancer development and progression as evaluated by the OR.\
**Notes:** Association between *CD44* mRNA expression with breast cancer risk compared with normal breast tissue (**A**), clinical TNM stage (**B**), T stage (**C**), N status (**D**), and histological grade (**E**). Association between CD44 protein and tumor grade (**F**).\
**Abbreviations:** CD44, cluster of differentiation 44; CI, confidence interval; OR, odds ratio; TNM, tumor--node--metastasis.](ott-9-431Fig2){#f2-ott-9-431}

![Association between CD44 expression and molecular subtype.\
**Notes:** Association between *CD44* mRNA with ER status (**A**), PR (**B**), HER2 (**C**), and basal--luminal (**D**). Association between CD44 protein with ER status (**E**), PR (**F**), HER2 (**G**), and basal--luminal (**H**).\
**Abbreviations:** CD44, cluster of differentiation 44; CI, confidence interval; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; OR, odds ratio; PR, progesterone receptor.](ott-9-431Fig3){#f3-ott-9-431}

![Forest plot for the correlation of *CD44* mRNA expression with breast cancer survival.\
**Notes:** Associations between *CD44* mRNA expression with breast cancer OS (**A**), RFS (**B**), MFS (**C**) in all population of breast cancer, and RFS (**D**) in patients with basal-like breast cancer.\
**Abbreviations:** CD44, cluster of differentiation 44; CI, confidence interval; HR, hazard ratio; MFS, metastasis-free survival; OS, overall survival; RFS, recurrence-free survival.](ott-9-431Fig4){#f4-ott-9-431}

![Kaplan--Meier survival curves for the correlation of *CD44* mRNA expression with breast cancer.\
**Notes:** (**A**) *CD44* mRNA expression with respect to OS in patients with breast cancer (GSE3143). *CD44* mRNA expression with respect to RFS (**B**) and MFS (**C**) in all patients with breast cancer (GSE6532). *CD44* mRNA expressions with respect to RFS in all patients (**D**), those with luminal subtype (**E**), and those with basal-like breast cancer (**F**) in database GSE25066.\
**Abbreviations:** CD44, cluster of differentiation 44; MFS, metastasis-free survival; OS, overall survival; RFS, recurrence-free survival.](ott-9-431Fig5){#f5-ott-9-431}

![*CD44* expression was associated with stem cell and EMT markers.\
**Notes:** Association between mRNA expressions of *CD44* with EMT-related genes *SNAI1* (**A**), *SLUG* (**B**), *ZEB1* (**C**), *CDH2* (**D**), *TWIST* (**E**), and *VIM* (**F**). Association between mRNA expression of *CD44* and stem cell factors *ALDH1* (**G**), *SOX2* (**H**), *NANOG* (**I**), *KLF4* (**J**), *MYC* (**K**), and *OCT4* (**L**).\
**Abbreviations:** CD44, cluster of differentiation 44; EMT, epithelial*--*mesenchymal transition.](ott-9-431Fig6){#f6-ott-9-431}

###### 

Characteristics of the included studies by CD44 mRNA expression in the meta-analysis

  References                            Year   Country or area   Duration (months)   Stage    Quality score   Detection    Cutoff values                 Patients with *CD44* overexpression (total number)
  ------------------------------------- ------ ----------------- ------------------- -------- --------------- ------------ ----------------------------- ----------------------------------------------------
  Desmedt et al[@b21-ott-9-431]         2007   Canada            NA                  NA       8               Microarray   Median expression: 9.34       99 (198)
  Heikkinen et al[@b27-ott-9-431]       2011   Finland           36                  NA       8               Microarray   Median expression: 11.05      92 (183)
  Terunuma et al[@b28-ott-9-431]        2014   USA               NA                  I--III   9               Microarray   Median expression: 11.12      31 (61)
  Sircoulomb et al[@b29-ott-9-431]      2010   France            240                 NA       7               Microarray   Median expression: 7.60       26 (51)
  Clarke et al[@b30-ott-9-431]          2013   Canada            180                 NA       8               Microarray   Median expression: NA         39 (77)
  Ma et al[@b31-ott-9-431]              2009   USA               36                  NA       7               Microarray   Median expression: 2.33       19 (38)
  Hatzis et al[@b32-ott-9-431]          2011   USA               120                 I--IV    9               Microarray   Median expression: 9.63       254 (508)
  Tofigh et al[@b33-ott-9-431]          2014   Canada            NA                  I--IV    8               Microarray   Median expression: 11.63      161 (321)
  Kao et al[@b34-ott-9-431]             2011   Taiwan            156                 I--IV    9               Microarray   Median expression: 8.06       164 (327)
  Minn et al[@b35-ott-9-431]            2005   USA               NA                  NA       8               Microarray   Median expression: 1,674.60   50 (99)
  Desmedt et al[@b36-ott-9-431]         2011   Canada            NA                  NA       8               Microarray   Median expression: 2.94       61 (120)
  Schmidt et al[@b37-ott-9-431]         2008   Germany           120                 NA       9               Microarray   Median expression: 1,595      100 (200)
  Nagalla et al[@b38-ott-9-431]         2013   USA               NA                  NA       8               Microarray   Median expression: 10.33      70 (139)
  Loi et al[@b39-ott-9-431]             2007   Canada            NA                  NA       9               Microarray   Median expression: 6.52       164 (327)
  Dedeurwaerder et al[@b40-ott-9-431]   2011   Canada            NA                  NA       8               Microarray   Median expression: 7.18       45 (90)
  Miller et al[@b41-ott-9-431]          2005   Singapore         NA                  NA       9               Microarray   Median expression: 8.04       126 (251)
  Symmans et al[@b42-ott-9-431]         2010   USA               NA                  NA       9               Microarray   Median expression: 10.78      149 (298)
  Pawitan et al[@b43-ott-9-431]         2005   Sweden            24                  NA       8               Microarray   Median expression: 7.04       80 (159)
  Wang et al[@b44-ott-9-431]            2005   USA               180                 NA       9               Microarray   Median expression: 1,285.15   143 (286)
  Hu et al[@b45-ott-9-431]              2009   USA               NA                  NA       7               Microarray   Median expression: NA         40 (80)
  Hennessy et al[@b46-ott-9-431]        2009   USA               NA                  NA       9               Microarray   Median expression: NA         47 (94)
  Bild et al[@b47-ott-9-431]            2006   USA               NA                  NA       9               Microarray   Median expression: 62.00      80 (158)
  Minn et al[@b48-ott-9-431]            2007   USA               NA                  NA       7               Microarray   Median expression: 1,636.50   29 (58)

**Abbreviations:** CD44, cluster of differentiation 44; NA, not available.

###### 

Characteristics of the included studies by CD44 protein abundance in the meta-analysis

  References                             Year   Country or area              Duration (months)   Stage   Quality score   Detection   Cutoff values                               Patients with CD44 overexpression (total number)
  -------------------------------------- ------ ---------------------------- ------------------- ------- --------------- ----------- ------------------------------------------- --------------------------------------------------
  Dan et al[@b22-ott-9-431]              2014   USA                          96                  I--II   8               IHC         Staining of score                           22 (51)
  Adamczyk et al[@b49-ott-9-431]         2014   Poland                       120                 NA      9               IHC         Percentage of immunopositive cells \>10%    70 (144)
  Wu et al[@b50-ott-9-431]               2013   USA                          144                 NA      8               IHC         Staining of *H*-score                       60 (126)
  Bernardi et al[@b51-ott-9-431]         2012   Brazil                       72                  I--IV   9               IHC         Staining of score                           55 (78)
  Uchoa Dde et al[@b52-ott-9-431]        2014   Brazil                       60                  NA      8               IHC         Percentage of immunopositive cells \>0.1%   34 (94)
  Ahmed et al[@b53-ott-9-431]            2012   Egypt                        96                  NA      9               IHC         Staining of *H*-score                       501 (786)
  Wang et al[@b54-ott-9-431]             2011   People's Republic of China   NA                  NA      8               IHC         Percentage of immunopositive cells \>10%    51 (117)
  Ricardo et al[@b55-ott-9-431]          2011   Portugal                     168                 NA      7               IHC         Percentage of immunopositive cells \>10%    237 (463)
  Kim et al[@b56-ott-9-431]              2011   Korea                        60                  NA      8               IHC         Percentage of immunopositive cells \>10%    173 (643)
  Giatromanolaki et al[@b57-ott-9-431]   2011   Greece                       156                 NA      9               IHC         Percentage of immunopositive cells \>10%    72 (139)
  Looi et al[@b58-ott-9-431]             2006   Malaysia                     NA                  NA      9               IHC         Percentage of immunopositive cells \>10%    24 (60)
  Han et al[@b59-ott-9-431]              2015   People's Republic of China   48                  I--IV   8               IHC         Staining of score: 0--2 vs 3--12            175 (325)

**Abbreviations:** CD44, cluster of differentiation 44; IHC, immunohistochemistry; NA, not available.
